Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yann Godbert

Showing results (21-30 of 36) with videos related to

Pageof 4
Sort By:
Acta Oncologica (Stockholm, Sweden)|November 10, 2023
Evaluating video-based consultations in routine clinical practice at a comprehensive cancer centerThibaut Mottet, Victor Hémar, Sylvia Enfedaque, et al.
Annales D'Endocrinologie|May 9, 2025
ENDOCAN TUTHYREF network consensus recommendations: Refractory follicular-derived thyroid cancerChristine Do Cao, Yann Godbert, Stéphane Bardet, et al.
Endocrine|March 26, 2021
Percutaneous thermal ablation of lung metastases from thyroid carcinomas. A retrospective multicenter study of 107 nodules. On behalf of the TUTHYREF networkFrançoise Bonichon, Thierry de Baere, Amandine Berdelou, et al.
The Lancet. Diabetes & Endocrinology|May 30, 2018
Outcome after ablation in patients with low-risk thyroid cancer (ESTIMABL1): 5-year follow-up results of a randomised, phase 3, equivalence trialMartin Schlumberger, Sophie Leboulleux, Bogdan Catargi, et al.
European Journal of Cancer (Oxford, England : 1990)|September 12, 2021
Intermittent versus continuous administration of pazopanib in progressive radioiodine refractory thyroid carcinoma: Final results of the randomised, multicenter, open-label phase II trial PAZOTHYRChristelle de la Fouchardière, Yann Godbert, Cécile Dalban, et al.
Frontiers in Endocrinology|July 17, 2024
Safety and efficacy of nintedanib as second-line therapy for patients with differentiated or medullary thyroid cancer progressing after first-line therapy. A randomized phase II study of the EORTC Endocrine Task Force (protocol 1209-EnTF)Sophie Leboulleux, Ellen Kapiteijn, Saskia Litière, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 7, 2021
Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid CancerLori J Wirth, Marcia S Brose, Eric J Sherman, et al.
Thyroid : Official Journal of the American Thyroid Association|March 30, 2017
Molecular Pathology of Anaplastic Thyroid Carcinomas: A Retrospective Study of 144 CasesBenjamin Bonhomme, Yann Godbert, Gaelle Perot, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 19, 2023
A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in Metastatic Radioactive Iodine Refractory BRAF p.V600E-Mutated Differentiated Thyroid CancerSophie Leboulleux, Christine Do Cao, Slimane Zerdoud, et al.
Trials|April 29, 2023
ESTIMation of the ABiLity of prophylactic central compartment neck dissection to modify outcomes in low-risk differentiated thyroid cancer: a prospective randomized trialDana Hartl, Yann Godbert, Xavier Carrat, et al.
Pageof 4

Showing results (21-30 of 36) with videos related to

Sort By:
Pageof 4
Acta Oncologica (Stockholm, Sweden)|November 10, 2023
Evaluating video-based consultations in routine clinical practice at a comprehensive cancer centerThibaut Mottet, Victor Hémar, Sylvia Enfedaque, et al.
Annales D'Endocrinologie|May 9, 2025
ENDOCAN TUTHYREF network consensus recommendations: Refractory follicular-derived thyroid cancerChristine Do Cao, Yann Godbert, Stéphane Bardet, et al.
Endocrine|March 26, 2021
Percutaneous thermal ablation of lung metastases from thyroid carcinomas. A retrospective multicenter study of 107 nodules. On behalf of the TUTHYREF networkFrançoise Bonichon, Thierry de Baere, Amandine Berdelou, et al.
The Lancet. Diabetes & Endocrinology|May 30, 2018
Outcome after ablation in patients with low-risk thyroid cancer (ESTIMABL1): 5-year follow-up results of a randomised, phase 3, equivalence trialMartin Schlumberger, Sophie Leboulleux, Bogdan Catargi, et al.
European Journal of Cancer (Oxford, England : 1990)|September 12, 2021
Intermittent versus continuous administration of pazopanib in progressive radioiodine refractory thyroid carcinoma: Final results of the randomised, multicenter, open-label phase II trial PAZOTHYRChristelle de la Fouchardière, Yann Godbert, Cécile Dalban, et al.
Frontiers in Endocrinology|July 17, 2024
Safety and efficacy of nintedanib as second-line therapy for patients with differentiated or medullary thyroid cancer progressing after first-line therapy. A randomized phase II study of the EORTC Endocrine Task Force (protocol 1209-EnTF)Sophie Leboulleux, Ellen Kapiteijn, Saskia Litière, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 7, 2021
Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid CancerLori J Wirth, Marcia S Brose, Eric J Sherman, et al.
Thyroid : Official Journal of the American Thyroid Association|March 30, 2017
Molecular Pathology of Anaplastic Thyroid Carcinomas: A Retrospective Study of 144 CasesBenjamin Bonhomme, Yann Godbert, Gaelle Perot, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 19, 2023
A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in Metastatic Radioactive Iodine Refractory BRAF p.V600E-Mutated Differentiated Thyroid CancerSophie Leboulleux, Christine Do Cao, Slimane Zerdoud, et al.
Trials|April 29, 2023
ESTIMation of the ABiLity of prophylactic central compartment neck dissection to modify outcomes in low-risk differentiated thyroid cancer: a prospective randomized trialDana Hartl, Yann Godbert, Xavier Carrat, et al.
Pageof 4